PROF.G. KARTHIKEYAN
MBBS, MD, DM, MSc
EXECUTIVE DIRECTOR
- MBBS
- MD
- DM (Cardiology)
- MSc (Health Research Methodology)
Dr Ganesan Karthikeyan is a clinical cardiologist and a Professor of Cardiology at the All India Institute of Medical Sciences, New Delhi, India. He completed his training at the All India Institute of Medical Sciences, New Delhi, and at McMaster University, Canada. He was an honorary Visiting Professor of Medicine and is now a Senior International Fellow of the Population Health Research Institute, at that University. He is a Fellow of the Academy of Medical Sciences, and National Academy of Sciences India (NASI). He is the Editor-in-Chief of the BMJ journal Open Heart and an Associate Editor of several other international cardiology journals.
His research is mainly focused on cardiovascular diseases affecting low- and middle-income countries, including valvular heart disease, particularly rheumatic heart disease (RHD), mechanical valve thrombosis, anticoagulation, and indigenous drug-eluting stents. He is one of the key leads of the INVICTUS international research program. He is a member of the Medical Technology Assessment Board (MTAB) of the Government of India, the Chair of the Technical Advisory Group reviewing cost-effectiveness of drugs and technologies for deployment, and a member of the expert panel devising cardiology reimbursement packages for the Indian government’s flagship insurance scheme, PMJAY. He is a member of the Governing Board of Rheumatic Heart Disease, Evidence, Advocacy, Communication, Hope (RhEACH), and also serves as an honorary consultant to the Human Health Division of the International Atomic Energy Agency (IAEA), providing advice in identifying, designing and implementing research protocols in resource-poor settings.
Publication
Selected recent publications
1. Karthikeyan G, Ntsekhe M, Islam S, et al. Mortality and morbidity in adults with rheumatic heart disease. JAMA 2024; doi:10.1001/jama.2024.825
2. Karthikeyan G, Kothari SS. How should the burden of rheumatic heart disease be reduced? Lancet Glob Health. 2023;11:e316-e317.
3. Karthikeyan G, et al. Research priorities for the secondary prevention and management of acute rheumatic fever and rheumatic heart disease: a National Heart, Lung, and Blood Institute workshop report. BMJ Glob Health 2023; 8(Suppl 9):e012468
4. Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. N Engl J Med 2022;387:978-988.
5. Karthikeyan G, Mantoo MR, Bhargava B. Choosing the right model for STEMI care in India - Focus should remain on providing timely fibrinolytic therapy, for now. Indian J Med Res 2022 Jul 21. doi: 10.4103/ijmr.ijmr_600_22.
6. Karthikeyan G, Fung E, Foo R S-Y. Alternative hypothesis to explain disease progression in rheumatic heart disease. Circulation 2020; 142:2091-2094.
7. Karthikeyan G, Connolly SJ, Yusuf S. Overestimation of stroke risk in rheumatic mitral stenosis and the implications for anticoagulation. Circulation 2020; 142: 1697-1699.
8. Karthikeyan G. Tracking the impact of interventions against COVID-19 in the absence of extensive testing. Indian J Med Res 2020;151(2 & 3):114-5.
9. Karthikeyan G, Devasenapathy N, Zuhlke L, Engel ME, Rangarajan S, Teo KK, et al. Digoxin and clinical outcomes in the Global Rheumatic Heart Disease Registry. Heart 2019;105:363-9.
10. Karthikeyan G, Guilherme L. Acute rheumatic fever. Lancet. 2018;392:161-74.
- GKARTHIKEYAN[AT]THSTI[DOT]RES[DOT]IN